SEC Tracker
Get the app

Acadia Pharmaceuticals ACAD

Laura Brege (Director) plans to sell 4,500 ACAD shares, about $112,240

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Jun 12, 2023
  2. Broker: Piper Sandler & Co.
  3. Shares acquired by: Vested RSU shares
  4. 10b5-1 plan adopted: Nov 14, 2022

All of Laura Brege's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 4,500 shares at $24.87 on Jun 12, 2023 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Acadia Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  2. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  3. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  4. Cytokinetics CYTK public float $2.5B, Jun 30, 2025
  5. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.